Original Article

Prostate Cancer and Prostatic Diseases (2010) 13, 126–131; doi:10.1038/pcan.2009.64; published online 19 January 2010

Accurate prediction of repeat prostate biopsy outcomes by a mitochondrial DNA deletion assay

K Robinson1, J Creed1, B Reguly1, C Powell1, R Wittock1, D Klein1, A Maggrah1, L Klotz2, R L Parr1 and G D Dakubo1

  1. 1Genesis Genomics, Thunder Bay, ON, Canada
  2. 2Division of Urology, Department of Surgery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada

Correspondence: Dr GD Dakubo, Genesis Genomics, 1000-290 Munro Street, Thunder Bay, ON P7A 7T1, Canada. E-mail: gabriel.dakubo@genesisgenomics.com

Received 10 September 2009; Revised 4 December 2009; Accepted 18 December 2009; Published online 19 January 2010.



Several cancers are characterized by large-scale mtDNA deletions. We previously provided evidence that one of these deletions has potential utility in resolving false from true-negative prostate needle biopsies. This study was to assess the clinical value of this deletion in predicting re-biopsy outcomes. We used a quantitative polymerase chain reaction assay to measure the levels of the deletion in individual negative needle biopsies from 101 patients who had a repeat biopsy within a year with known outcomes. Using an empirically established cycle threshold (Ct) cutoff of 31, and the lowest Ct for each patient as diagnostic of prostate cancer, as well as the histopathologic diagnosis on second biopsy, we calculated the clinical performance of the deletion. The Ct cutoff at 31 gave a sensitivity and specificity of 84 and 54%, respectively, with the area under a receiver-operating characteristics curve of 0.749. The negative predictive value was 91%. The assay was able to predict the presence of a missed tumor in 17 out of 20 men a year before diagnosis. This ancillary test appears to identify men who do not require a repeat biopsy with a high degree of certainty. The results suggest that the majority of men with atypical small acinar proliferation have a concurrent missed tumor and therefore require close monitoring for early detection.


Negative prostate needle biopsies; mtDNA deletion; negative predictive value; field cancerization



These links to content published by NPG are automatically generated


Prostate cancer: diagnosis and staging

Asian Journal of Andrology Review

Prostate biopsy strategies

Nature Clinical Practice Urology Review (01 Sep 2007)

See all 4 matches for Reviews

Extra navigation